Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt

Figure 2

(a) mRNA was extracted from 11 colon cancer cell lines, and the expression of MEIS3 was detected by western blot (). (b) The LOVO cells were transfected with random shRNA, CON vector, and MEIS3 shRNA, and the knockdown efficiency was confirmed by western blot after 48 h. (c) The LOVO-CON and MEIS3 shRNA cells were treated with different concentrations of cetuximab for 48 h, and PI staining was used to detect changes in the cell cycle. (d) The LOVO-CON and MEIS3 shRNA cells were treated with different concentrations of cetuximab for 48 h, and the cell viability was detected using an MTT assay. (e) The SNU-61 cells were transfected with CON and MEIS3 cDNA, and the expression of MEIS3 at the protein level was detected by western blot after 48 h (). (f) The SNU-61 CON and MEIS3 groups were treated with different concentrations of cetuximab for 48 h, and PI staining was used to detect changes in the cell cycle. (g) The SNU-61 CON and MEIS3 groups were treated with different concentrations of cetuximab for 48 h, and cell viability was detected using an MTT assay. (h) The LOVO and LOVO MEIS3 shRNA cells were treated with 0.5 μg/ml cetuximab for 48 h while the SNU-61 and SNU-61 MEIS3 were treated with 0.125 μg/ml cetuximab for 48 h, and the change in apoptosis was detected using the Annexin V/PI double staining.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)